Welcome to our dedicated page for Arvinas news (Ticker: ARVN), a resource for investors and traders seeking the latest updates and insights on Arvinas stock.
Arvinas, Inc. develops targeted protein degradation medicines through its PROTAC protein degrader platform. Company updates center on VEPPANU (vepdegestrant), developed with Pfizer and approved by the FDA for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after endocrine-based therapy, as well as regulatory, clinical, and corporate milestones tied to that program.
Arvinas news also covers investigational PROTAC degraders across oncology, neurology, and neuromuscular disease, including ARV-102 for LRRK2-driven neurodegenerative disorders, ARV-806 for KRAS G12D-mutated cancers, ARV-393 for BCL6-driven lymphoma, and ARV-027 as a polyQ-AR degrader. Recurring items include clinical data presentations, financial results, corporate updates, investor conferences, and governance changes.
Arvinas and Pfizer have announced promising updates on ARV-471, a novel estrogen receptor degrader for treating ER+/HER2- breast cancer, presented at the San Antonio Breast Cancer Symposium. Latest Phase 1 data shows a clinical benefit rate of 40% among heavily pretreated patients, with three confirmed partial responses. The drug shows favorable tolerability, with 89% ER degradation. Phase 3 clinical trials are anticipated to begin in 2022, supporting ARV-471's potential as a new standard of care.
Arvinas, Inc. (NASDAQ: ARVN) and Pfizer Inc. (NYSE: PFE) announced updated safety and efficacy data from the Phase 1 trial of ARV-471, an oral estrogen receptor-targeting PROTAC protein degrader. The presentation will take place at the San Antonio Breast Cancer Symposium on December 10, 2021. ARV-471 is aimed at treating locally advanced or metastatic ER+/HER2- breast cancer. Preclinical studies indicated strong tumor shrinkage and ER degradation. Arvinas and Pfizer share development costs and profits as part of their collaboration.
Arvinas, a clinical-stage biotechnology company (Nasdaq: ARVN), has announced that its CFO Sean Cassidy and CSO Ian Taylor will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference. This event is scheduled for November 16 at 10:40 a.m. ET. A live audio webcast of the presentation will be available on Arvinas’ website, with a replay accessible for 30 days post-event.
Arvinas focuses on developing therapies that degrade disease-causing proteins using its proprietary PROTAC® platform, targeting prostate and breast cancer.
Arvinas, Inc. (Nasdaq: ARVN) announced its Q3 2021 financial results, highlighting key advancements in drug development and a strategic collaboration with Pfizer. The company reported cash reserves of $1.55 billion, a significant increase from $688.5 million at the end of 2020, largely due to the Pfizer collaboration. Revenues rose to $9.3 million, driven by collaboration agreements. However, net loss widened to $46.8 million, influenced by rising R&D and administrative expenses. Arvinas plans to initiate multiple Phase 3 studies for its lead drug ARV-471 in 2022.
Arvinas, a biotechnology company focused on targeted protein degradation, announced participation in two virtual investor conferences. The Citi 16th Annual BioPharma Virtual Conference is scheduled for September 9, 2021, featuring a fireside chat at 9:45 a.m. ET with CEO John Houston and CMO Ron Peck. The 2021 Cantor Virtual Global Healthcare Conference will take place on September 28, 2021, at 9:20 a.m. ET, with CFO Sean Cassidy and CSO Ian Taylor. Arvinas aims to develop therapies using its PROTAC® platform to treat various cancers.
Insilico Medicine has announced a strategic R&D collaboration with Arvinas (NASDAQ: ARVN), focusing on integrating artificial intelligence with PROTAC technology for drug development. This partnership aims to design innovative treatment modalities for various targets, leveraging AI's potential in drug discovery. Insilico has also recently completed a $255 million funding round and nominated its second preclinical candidate for kidney fibrosis. This collaboration signifies a pivotal move in the biotech sector, enhancing the capabilities of both companies in developing transformative therapeutics.
Arvinas, Inc. (Nasdaq: ARVN) reported Q2 2021 financial results, showing a net loss of $50.3 million compared to $25.2 million a year earlier. The company announced a collaboration with Pfizer for its PROTAC degrader ARV-471, receiving an upfront payment of $650 million and a $350 million equity investment. R&D expenses increased to $43 million, while revenue slightly decreased to $5.5 million. As of June 30, 2021, cash and marketable securities totaled $605.1 million. Key milestones include upcoming Phase 1 trial data presentations for ARV-471 and ARV-110.
Arvinas and Pfizer have formed a global collaboration to develop ARV-471, an investigational breast cancer therapy currently in Phase 2 development for ER+/HER2- patients. The agreement includes a $650 million upfront payment from Pfizer, alongside a $350 million equity investment in Arvinas, granting Pfizer approximately 7% ownership. Profit and cost sharing will be 50/50 worldwide, with potential milestone payments reaching $1.4 billion. This partnership aims to leverage Pfizer's oncology expertise to enhance the commercial potential of ARV-471.
Arvinas, Inc. (Nasdaq: ARVN) announced a groundbreaking ceremony for a new 525,000-square-foot building at 101 College Street in New Haven, scheduled to serve as its headquarters starting in 2024. The company will occupy around 160,000 square feet, promoting its growth and contributing to the local biopharmaceutical sector. The construction project is part of New Haven's Downtown Crossing initiative, funded by various public entities, aimed at revitalizing the area and enhancing connectivity within the life sciences district.
Arvinas, a clinical-stage biotechnology company (Nasdaq: ARVN), announced participation in the 42nd Annual Goldman Sachs Global Healthcare Conference on June 10 at 10:30 a.m. ET. Chief Medical Officer Ron Peck, M.D., and Chief Financial Officer Sean Cassidy will engage in a fireside chat. The event will be available via live audio webcast on Arvinas’ website, with a replay accessible for 30 days. Arvinas focuses on developing therapies that target and degrade disease-causing proteins using its innovative PROTAC® technology.